MedTrace Logo

Safety and Efficacy of CD10367 in Psoriasis Vulgaris

NCT03025282 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

This was an exploratory, single-center, investigator blinded, randomized, controlled, intra-individual study, involving participants with psoriasis vulgaris.

The objective was to evaluate, in a modified Dumas-Scholtz psoriasis mini-zone test, the safety and efficacy of CD10367 solution at 1% and 3% after a 3-week treatment period of once daily application.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

CD10367 3% Solution - Non-desquamated zone

Once daily application for 3 weeks

DRUG

CD10367 1% Solution - Non-desquamated zone

Once daily application for 3 weeks

DRUG

CD10367 solution placebo - Non-desquamated zone

Once daily application for 3 weeks

DRUG

Betneval ointment - Non-desquamated zone

Once daily application for 3 weeks

DRUG

CD10367 3% Solution - Desquamated zone

Once daily application for 3 weeks

DRUG

CD10367 solution placebo - Desquamated zone

Once daily application for 3 weeks

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-03
Primary Completion
2017-03-24
Completion
2017-03-24

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03025282 on ClinicalTrials.gov